DNA topoisomerase II rescue by catalytic inhibitors. A new strategy to improve the antitumor selectivity of etoposide

Biochemical Pharmacology

Volumn 54, Issue 7, 1997, Pages 755-759

  Jensen, Peter Buhl ^a   Sehested, Maxwell ^b  

^a FINSEN LABORATORY   (Denmark)

^b University of Copenhagen   (Denmark)

Author keywords

Bisdioxopiperazine; Etoposide; High dose treatment; Topoisomerase II; Tumor selectivity

Indexed keywords

2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; ACLARUBICIN; AMSACRINE; ANTINEOPLASTIC AGENT; CHLOROQUINE; CLEROCIDIN; CP 115953; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ELLIPTICINE; ETOPOSIDE; FOSTRIECIN; GYRASE INHIBITOR; INTERCALATING AGENT; MERBARONE; MITOXANTRONE; NOVOBIOCIN; RAZOXANE; SURAMIN; TENIPOSIDE; UNCLASSIFIED DRUG;

ANIMAL MODEL; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA STRAND BREAKAGE; DOSE RESPONSE; DRUG MEGADOSE; DRUG TARGETING; ENZYME ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0000191348     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00116-0     Document Type: Note

References (28)

1. Chen AY and Liu LF, DNA topoisomerases - Essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34: 191-218, 1994.
2. Hansen HH, Management of small-cell cancer of the lung. Lancet 339: 846-849, 1992.
3. Wang JC, DNA topoisomerases. Annu Rev Biochem 65: 635-692, 1996.
4. Pommier Y, Kerrigan D, Schwartz RE, Swack JA and McCurdy A, Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res 46: 3075-3081, 1986.
5. Danks MK, Schmidt CA, Cirtain MC, Suttle DP and Beck WT, Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27: 8861-8869, 1988.
6. Jensen PB, Sørensen BS, Sehested M, Demant EJF, Kjeldsen E, Friche E and Hansen HH, Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. Biochem Pharmacol 45: 2025-2035, 1993.
7. de Jong S, Zijlstra JG, Mulder NH and de Vries EGE, Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance. Cancer Chemother Pharmacol 28: 461-464, 1991.
8. Ishida R, Hamatake M, Wasserman RA, Nitiss JL, Wang JC and Andoh T, DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Cancer Res 55: 2299-2303, 1995.
9. Jensen PB, Sørensen BS, Demant EJF, Sehested M, Jensen PS, Vindeløv L and Hansen HH, Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res 50: 3311-3316, 1990.
10. Jensen PB, Jensen PS, Demant EJF, Friche E, Sørensen BS, Sehested M, Wassermann K, Vindeløv L, Westergaard O and Hansen HH, Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: Relationship to DNA integrity and topoisomerase II. Cancer Res 51: 5093-5099, 1991.
11. Drake FH, Hofmann GA, Mong S, Bartus JL, Hertzberg RP, Johnson RK, Mattern MR and Mirabelli CK, In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 49: 2578-2583, 1989.
12. Boritzki TJ, Wolfard TS, Besserer JA, Jackson RC and Fry DW, Inhibition of type II topoisomerase by fostriecin. Biochem Pharmacol 37: 4063-4068, 1988.
13. Lee FYF, Flannery DJ and Siemann DW, Modulation of the cell cycle-dependent cytotoxicity of adriamycin and 4-hydroperoxycyclophosphamide by novobiocin, an inhibitor of mammalian topoisomerase-II. Cancer Res 52: 3515-3520, 1992.
14. Bojanowski K, Lelievre S, Markovits J, Couprie J, Jacquemin-Sablon A and Larsen AK, Suramin is an inhibitor of DNA topoisomerase-II in vitro and in Chinese hamster fibrosarcoma cells. Proc Natl Acad Sci USA 89: 3025-3029, 1992.
15. Jensen PB, Sørensen BS, Sehested M, Grue P, Demant EJF and Hansen HH, Targeting the cytotoxicity of topoisomerase II directed epipodophyllotoxins to tumor cells in acidic environments. Cancer Res 54: 2959-2963, 1994.
16. Woynarowski JM, Sigmund RD and Beerman TA, DNA minor groove binding agents interfere with topoisomerase II mediated lesions induced by epipodophyllotoxin derivative VM-26 and acridine derivative m-AMSA in nuclei from L1210 cells. Biochemistry 28: 3850-3855, 1989.
17. Tanabe K, Ikegami Y, Ishida R and Andoh T, Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 51: 4903-4908, 1991.
18. Ishida R, Miki T, Narita T, Yui R, Sato M, Utsumi KR, Tanabe K and Andoh T, Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: Mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 51: 4909-4916, 1991.
19. Sehested M, Jensen PB, Sørensen BS, Holm B, Friche E and Demant EJF, Antagonistic effect of the cardioprotector ( + )-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 46: 389-393, 1993.
20. Sørensen BS, Sinding J, Andersen AH, Alsner J, Jensen PB and Westergaard O, Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events. J Mol Biol 228: 778-786, 1992.
21. Rowe T, Kupfer G and Ross W, Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA-cleavage. Biochem Pharmacol 34: 2483-2487, 1985.
22. Roca J, Ishida R, Berger JM, Andoh T and Wang JC, Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 91: 1781-1785, 1994.
23. Roca J and Wang JC, DNA transport by a type II DNA topoisomerase: Evidence in favor of a two-gate mechanism. Cell 77: 609-616, 1994.
24. Sehested M and Jensen PB, Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol 51: 879-886, 1996.
25. Hansen OP, Pedersen-Bjergaard J, Ellegaard J, Brincker H, Boesen AM, Christensen BE, Drivsholm A, Hippe E, Jans H, Jensen KB, Killmann SA, Jensen MK, Karle H, Laursen B, Nielsen JB, Nissen NI and Thorling K, Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia - A Danish national phase-III trial. Leukemia 5: 510-516, 1991.
26. Ackland SP and Schilsky RL, High-dose methotrexate: A critical reappraisal. J Clin Oncol 5: 2017-2031, 1987.
27. Holm B, Jensen PB and Sehested M, ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors. Cancer Chemother Pharmacol 38: 203-209, 1996.
28. Holm B, Jensen PB, Sehested M and Hansen HH, In vivo inhibition of etoposide-mediated apoptosis, toxicity, and antitumor effect by the topoisomerase II-uncoupling anthracycline aclarubicin. Cancer Chemother Pharmacol 34: 503-508, 1994.